Key Points
- CEO Benjamin Palleiko sold 7,294 KalVista shares on Dec. 8 at an average price of $16.51 (proceeds $120,423.94), reducing his holdings by 1.69% to 424,520 shares valued at about $7.01 million.
- KalVista recently beat quarterly estimates with EPS of ($0.92) vs. ($0.96) expected and revenue of $13.69 million vs. $6.03 million estimated, while the stock trades near $16 with a 1‑year range of $7.30–$17.28.
- Institutional buying has increased (notable new/larger stakes from Tudor, Parkman and Ameriprise) and analysts hold a consensus "Moderate Buy" rating with a $26.63 average price target.
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) CEO Benjamin Palleiko sold 7,294 shares of the business's stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $16.51, for a total value of $120,423.94. Following the sale, the chief executive officer owned 424,520 shares of the company's stock, valued at approximately $7,008,825.20. This trade represents a 1.69% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.
KalVista Pharmaceuticals Stock Performance
NASDAQ KALV opened at $16.16 on Wednesday. The company has a debt-to-equity ratio of 8.18, a current ratio of 7.22 and a quick ratio of 7.21. The stock's 50 day simple moving average is $12.47 and its 200-day simple moving average is $13.09. The company has a market cap of $816.89 million, a PE ratio of -4.09 and a beta of -0.14. KalVista Pharmaceuticals, Inc. has a 1-year low of $7.30 and a 1-year high of $17.28.
KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last posted its quarterly earnings data on Monday, November 10th. The specialty pharmaceutical company reported ($0.92) EPS for the quarter, beating the consensus estimate of ($0.96) by $0.04. The firm had revenue of $13.69 million during the quarter, compared to analyst estimates of $6.03 million. As a group, equities research analysts anticipate that KalVista Pharmaceuticals, Inc. will post -3.56 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in the business. Tudor Investment Corp ET AL acquired a new stake in KalVista Pharmaceuticals during the third quarter worth $24,360,000. Parkman Healthcare Partners LLC grew its holdings in shares of KalVista Pharmaceuticals by 155.5% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 1,735,003 shares of the specialty pharmaceutical company's stock worth $21,132,000 after purchasing an additional 1,055,940 shares during the period. Ameriprise Financial Inc. increased its position in shares of KalVista Pharmaceuticals by 2,258.6% during the 2nd quarter. Ameriprise Financial Inc. now owns 945,125 shares of the specialty pharmaceutical company's stock worth $10,685,000 after purchasing an additional 905,053 shares during the last quarter. Freestone Grove Partners LP acquired a new position in KalVista Pharmaceuticals in the third quarter valued at about $8,580,000. Finally, Schroder Investment Management Group boosted its stake in KalVista Pharmaceuticals by 108.7% during the third quarter. Schroder Investment Management Group now owns 1,158,457 shares of the specialty pharmaceutical company's stock worth $14,145,000 after buying an additional 603,499 shares during the period.
Wall Street Analysts Forecast Growth
Several research firms have recently weighed in on KALV. JMP Securities raised their price target on shares of KalVista Pharmaceuticals from $27.00 to $28.00 and gave the stock a "market outperform" rating in a research note on Friday, September 12th. Wall Street Zen upgraded shares of KalVista Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday. Weiss Ratings restated a "sell (d-)" rating on shares of KalVista Pharmaceuticals in a research report on Wednesday, October 8th. Citizens Jmp reduced their price objective on KalVista Pharmaceuticals from $29.00 to $28.00 and set a "market outperform" rating on the stock in a research report on Tuesday, November 11th. Finally, Citigroup reissued a "market outperform" rating on shares of KalVista Pharmaceuticals in a research note on Tuesday, November 11th. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $26.63.
Get Our Latest Analysis on KalVista Pharmaceuticals
KalVista Pharmaceuticals Company Profile
(
Get Free Report)
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
